RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals FDA Compliance for Peptide Therapy and BPC 157 Holt Law In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement Stevens & Lee Demand for Unapproved Weight Loss Drug Surges on Social Media MedPage Today